Seizure Disorder Clinical Trials
Sutter Health participates in clinical trials related to Seizure Disorder throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.
Title: A Prospective, Open-label Study of the Structure and Function of the Retina in Adult Patients with Refractory Complex Partial Seizures Treated with Vigabatrin (Sabril®) (Lundbeck, Inc., Protocol 13098A)Opens in a new window 
strong>Description: The purpose of the study is to evaluate the change in visual fields by means of automated static perimetry and to evaluate the change in retinal structure by means of spectral domain optical coherence tomography (SD-OCT) in adult patients with refractory complex partial seizures (CPS) being treated with vigabatrin (Sabril®).
Investigator: Kenneth Laxer, MD
Eligibility: Medically refractory complex partial seizures (min 2 or more/month), no pre-existing ocular disease.
Status: Active and open to enrollment
Location: California Pacific Medical Center
Contact: Doug Raggett, RN 415-600-3777 Email: RaggettD@sutterhealth.org
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 years old) with Partial Onset Seizures (Schwarz Biosciences, Inc. Protocol N01358) Opens in a new window
Description: This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.
Investigator: David King-Stephens, MD
Eligibility: Age 16 years to 80 years Epilepsy partial onset seizures.
Status: Active and open to enrollment
Location: California Pacific Medical Center
Contact: Doug Raggett, RN 415-600-3777 Email: RaggettD@sutterhealth.org
Title: RNS™ System Long-Term treatment Clinical Investigation (NeuroPace, Inc., Protocol #NP10005, DN 1009075) Opens in a new window
Description: This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
Investigator: David King-Stephens, MD
Eligibility: Age 16 years or older Epilepsy partial onset seizures.
Status: Active and open to enrollment
Location: California Pacific Medical Center
Contact: Doug Raggett, RN 415-600-3777
> See All Neurology Clinical Trials by Condition